AUP-16 multi-targeting therapy for chronic wounds (Diabetic Foot Ulcers...) shows 50% improvement vs placebo in Phase-2 RCT

MV-010 is an orally available recombinant bacterial enzyme formulated by an exclusively licensed platform to restore intestinal immune system homeostasis in inflammatory bowel disease (IBD).